Interviews

Alexander Spira, MD, PhD, discusses the phase 1 CHRYSALIS trial of amivantamab plus lazertinib in 2 EGFR-mutant non–small cell lung cancer patient populations, which include patients with relapsed/refractory and those who are treatment-naive.

Pavlos Msaouel, MD, PhD, discusses how the treatments and outcomes differ between patients with the rarer disease of renal medullary carcinoma than the more common renal cell carcinoma.

Ketan K. Badani, MD, discusses whether cytoreductive nephrectomies are efficacious when combined with immunotherapeutic agents in patients with renal cell carcinoma.

Marc J. Braunstein, MD, PhD, discusses chimeric antigen receptor T-cell therapies, Bruton’s kinase inhibitors, and brentuximab vedotin that were highlighted at the 2020 Chemotherapy Foundation Symposium.

Loretta J. Nastoupil, MD, discusses the use of off-the-shelf chimeric antigen receptor T-cell products for the treatment of patients with diffuse large B-cell lymphoma and other cancers.

Benjamin Levy, MD, discusses how the role of immunotherapy has evolved in the treatment landscape of lung cancer and where he sees this research headed in the future.

Ulka Vaishampayan, MD, discusses the findings from the phase 3 CheckMate-9ER study, which demonstrated promising response and survival outcomes with the combination of cabozantinib plus nivolumab as treatment of patients with metastatic renal cell carcinoma compared with sunitinib.

Ghassan K. Abou-Alfa, MD, discusses the therapies being used to treat patients with hepatocellular carcinoma right now.

Shaji K. Kumar, MD, addresses an important unanswered question that remains in the treatment landscape of newly diagnosed multiple myeloma, which is whether 3- or 4-drug regimens should be used in the frontline setting.

Andre Goy, MD, MS, discusses the benefits of working with a pathologist to develop a better understanding of molecular oncology and optimal treatment decisions for patients with lymphomas.

Natalie I. U. Vokes, MD, discusses the future of predicting how patients will respond to treatment, especially immunotherapy, based on their genomic profile.

Bradley McGregor, MD, discusses the current treatment landscape for patients with advanced or metastatic renal cell carcinoma, which has significantly evolved over the last few years.

Yelena Y. Janjigian, MD, discusses the differences between biomarker testing at academic centers versus community centers for patients with gastric cancer.

Naomi Haas, MD, discusses several areas of interest for the treatment of patients with prostate cancer that are utilizing PSMA, including bispecific T-cell engager antibodies, chimeric antigen receptor T cells, and the lutetium studies.

Paul Boutros, PhD, MBA, discusses the reasons why some patients with prostate cancer have more aggressive disease than others.

Michael Wang, MD, discusses current and upcoming treatments being investigated for patients with mantle cell lymphoma.

Guillermo Garcia-Manero, MD, discusses how the recently approved combination regimen of decitabine and cedazuridine fits into the treatment landscape for patients with myelodysplastic syndromes.

Masahiro Tsuboi, MD, discusses the key takeaways from the findings for osimertinib in patients with early-stage EGFR-mutant non–small cell lung cancer following a complete tumor resection in the phase 3 ADAURA clinical trial.

Matthew S. Davids, MD, MMSc, discusses the current treatment landscape for patients with chronic lymphocytic leukemia beyond chemoimmunotherapy.

Maria E. Cabanillas, MD, discusses the treatment landscape for patients with thyroid cancers harboring a TRK fusion.

Vivek Subbiah, MD, discusses how the data from selpercatinib have generated excitement for precision medicine in the treatment landscape for patients with RET-driven lung cancer.

Kenneth C. Anderson, MD, discusses how he has seen the treatment paradigm transform over the last decade in multiple myeloma.

Neeraj Agarwal, MD, discusses the efficacy of nivolumab and cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma in the phase 3 CheckMate-9ER trial.

Grzegorz S. Nowakowski, MD, discusses the remaining unmet needs that exist in the treatment landscape of diffuse large B-cell lymphoma.

Neal D. Shore, MD, FACS, discusses the results of the retrospective review on real-world patterns of genomic testing in patients with metastatic castration-resistant prostate cancer.

Lori A. Leslie, MD, discusses the approval of tazemetostat in the follicular lymphoma setting and the data that that led to its FDA approval.

Michael J. Pishvaian, MD, PhD, discusses the key takeaway from his presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology on the role of genetic testing in patients with pancreatic cancer.

Ghassan K. Abou-Alfa, MD, discusses the evolution of the treatment landscape in hepatocellular carcinoma.

Nancy U. Lin, MD, discusses the results from a substudy of HER2CLIMB looking at tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer and brain metastases.

Rana R. McKay, MD, discusses the combination of nivolumab and cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.